Regeneron

$376.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.26 (+1.14%) Today
$0.00 (0.00%) As of 6:54 PM EST after-hours

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Employees
7,400
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
40.86B
Price-Earnings Ratio
20.00
Dividend Yield
0.00
Average Volume
820.66K
High Today
$379.10
Low Today
$373.07
Open Price
$376.16
Volume
995.84K
52 Week High
$442.00
52 Week Low
$271.37

Collections

REGN News

Reuters21h

Edited Transcript of REGN earnings conference call or presentation 5-Nov-19 1:30pm GMT

Q3 2019 Regeneron Pharmaceuticals Inc Earnings Call TARRYTOWN Dec 13, 2019 (Thomson StreetEvents) -- Edited Transcript of Regeneron Pharmaceuticals Inc earning
3
BenzingaDec 10

Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were rebounding Tuesday as investors digested French pharma giant and collaboration partner Sanofi SA's (NAS
151
MarketWatchDec 10

Regeneron shares fall on Sanofi's new direction

Sanofi fr:sny and Regeneron Pharmaceuticals REGN, -1.78% announced plans to restructure two drug-development collaborations after Sanofi announced a new directi
58

REGN Earnings

$4.32
$5.16
$6.00
$6.84
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Feb 6, Pre-Market

You May Also Like

More REGN News

MarketWatchDec 10

Regeneron shares fall as Sanofi signals stake sale

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.54% slipped more than 3% in premarket trading Tuesday after French partner Sanofi SA (SAN.FR) indicated it wou
41
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.
Search
LearnBlogCareersHelpLog InSign Up